menu
    • menu
    [{"orgOrder":0,"company":"Sumitomo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"TP-1287","moa":"CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo \/ Not Applicable"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"TP-3654","moa":"PIM","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sumitomo \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo \/ Not Applicable"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"DSP-0390","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sumitomo \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo \/ Not Applicable"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"TP-3654","moa":"PIM kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sumitomo \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo \/ Not Applicable"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"JAPAN","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"DSP-0187","moa":"","graph1":"Sleep","graph2":"Phase I","graph3":"Sumitomo","amount2":1.1399999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":1.1399999999999999,"dosageForm":"Oral","sponsorNew":"Sumitomo \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Kyorin Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"JAPAN","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Vibegron","moa":"","graph1":"Urology","graph2":"Approved","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sumitomo \/ Sumitomo","highestDevelopmentStatusID":"12","companyTruncated":"Sumitomo \/ Sumitomo"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ulotaront","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sumitomo \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Vibegron","moa":"","graph1":"Urology","graph2":"Phase III","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sumitomo \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo \/ Not Applicable"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Salipro Biotech","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Sumitomo \/ Sumitomo","highestDevelopmentStatusID":"3","companyTruncated":"Sumitomo \/ Sumitomo"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Gedeon Richter","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"HUNGARY","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Relugolix","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sumitomo \/ Sumitomo","highestDevelopmentStatusID":"12","companyTruncated":"Sumitomo \/ Sumitomo"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Relugolix","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sumitomo \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"Sumitomo \/ Pfizer Inc"}]

    Find Clinical Drug Pipeline Developments & Deals by Sumitomo

    Menu

    Sumitomo

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sumitomo

                            Japan arrow
                            Antibody Engineering
                            Not Confirmed

                            Sumitomo

                            Japan arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Relugolix,Estradiol,Norethisterone Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved

                            Sponsor : Pfizer Inc

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sumitomo Pharma and Pfizer in Canada Receive Health Canada Approval for MYFEMBREE®

                            Details : Myfembree (relugolix, estradiol, and norethindrone acetate) has received a dual indication approval, making it the first Health Canada-approved oral treatment to manage uterine fibroids and endometriosis.

                            Brand Name : Myfembree

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 19, 2023

                            Lead Product(s) : Relugolix,Estradiol,Norethisterone Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved

                            Sponsor : Pfizer Inc

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sumitomo

                            Japan arrow
                            Antibody Engineering
                            Not Confirmed

                            Sumitomo

                            Japan arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Relugolix,Estradiol,Norethisterone Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Recipient : Gedeon Richter

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Gedeon Richter and Sumitomo Pharma Receive Positive CHMP Opinion for RYEQO® for Treatment of Endometriosis

                            Details : Ryeqo (relugolix, estradiol, and norethisterone acetate) receives positive opinion by CHMP recommending approval in for the adjuvant treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.

                            Brand Name : Ryeqo

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 15, 2023

                            Lead Product(s) : Relugolix,Estradiol,Norethisterone Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Recipient : Gedeon Richter

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sumitomo

                            Japan arrow
                            Antibody Engineering
                            Not Confirmed

                            Sumitomo

                            Japan arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery Platform

                            Recipient : Salipro Biotech

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Salipro Biotech enters into research collaboration with Sumitomo Pharma to advance a drug discovery program

                            Details : Through collaboration, Salipro will utilize its expertise in stabilizing challenging membrane proteins via its Salipro® technology to advance Sumitomo's drug discovery program by characterizing a drug with the desired therapeutic properties against a se...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 12, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery Platform

                            Recipient : Salipro Biotech

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sumitomo

                            Japan arrow
                            Antibody Engineering
                            Not Confirmed

                            Sumitomo

                            Japan arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vibegron

                            Therapeutic Area : Urology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sumitomo Pharma Announces Positive Topline Results from Phase 3 Clinical Studies Evaluating Vibegron in Men wi...

                            Details : Gemtesa (vibegron) is a once-daily beta-3 adrenergic receptor (β3) agonist, is currently under investigation for the treatment of men with overactive bladder (OAB) symptoms receiving pharmacological therapy for benign prostatic hyperplasia.

                            Brand Name : Gemtesa

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 11, 2023

                            Lead Product(s) : Vibegron

                            Therapeutic Area : Urology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sumitomo

                            Japan arrow
                            Antibody Engineering
                            Not Confirmed

                            Sumitomo

                            Japan arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ulotaront

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Sponsor : Otsuka Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 DIAMOND 1 and DIAMOND 2 Clinical Studies Eval...

                            Details : SEP-363856 (ulotaront) is a TAAR1 agonist with 5-HT1A agonist activity, is currently under investigation for the treatment of schizophrenia, generalized anxiety disorder and the adjunctive treatment of MDD with additional indications under consideration.

                            Brand Name : SEP-363856

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 31, 2023

                            Lead Product(s) : Ulotaront

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Sponsor : Otsuka Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sumitomo

                            Japan arrow
                            Antibody Engineering
                            Not Confirmed

                            Sumitomo

                            Japan arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vibegron

                            Therapeutic Area : Urology

                            Study Phase : Approved

                            Recipient : Kyorin Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Kyorin And Sumitomo Pharma Enter Into License Agreement Of Vibegron In Taiwan And Other Asian Countries

                            Details : KYORIN will grant Sumitomo Pharma the exclusive rights to develop, manufacture, and commercialize the therapeutic agent for OAB called Vibegron in in Taiwan and Other Asian Countries, and Sumitomo Pharma will develop, manufacture, and commercialize the C...

                            Brand Name : Gemtesa

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 06, 2023

                            Lead Product(s) : Vibegron

                            Therapeutic Area : Urology

                            Highest Development Status : Approved

                            Recipient : Kyorin Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sumitomo

                            Japan arrow
                            Antibody Engineering
                            Not Confirmed

                            Sumitomo

                            Japan arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TP-3654

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sumitomo Pharma Oncology to Present Preliminary Clinical Data Evaluating Investigational Agent TP-3654 at the ...

                            Details : TP-3654 is an oral investigational inhibitor of PIM kinases, which has shown potential antitumor and anti-fibrotic activity through multiple pathways, including induction of apoptosis in preclinical models.

                            Brand Name : TP-3654

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 03, 2022

                            Lead Product(s) : TP-3654

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Sumitomo

                            Japan arrow
                            Antibody Engineering
                            Not Confirmed

                            Sumitomo

                            Japan arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DSP-0390

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sumitomo Pharma Oncology Receives Orphan Drug Designation for DSP-0390, an Investigational Emopamil-binding Pr...

                            Details : DSP-0390 is an investigational emopamil-binding protein (EBP) inhibitor. EBP is an endoplasmic reticulum membrane protein involved in cholesterol biosynthesis.

                            Brand Name : DSP-0390

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 18, 2022

                            Lead Product(s) : DSP-0390

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Sumitomo

                            Japan arrow
                            Antibody Engineering
                            Not Confirmed

                            Sumitomo

                            Japan arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TP-3654

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sumitomo Pharma Oncology Receives Orphan Drug Designation for TP-3654, an Investigational Oral Inhibitor of PI...

                            Details : TP-3654 is an oral investigational inhibitor of PIM kinases, which has potential antitumor and anti-fibrotic effects through multiple pathways, including induction of apoptosis.

                            Brand Name : TP-3654

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 08, 2022

                            Lead Product(s) : TP-3654

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Sumitomo

                            Japan arrow
                            Antibody Engineering
                            Not Confirmed

                            Sumitomo

                            Japan arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DSP-0187

                            Therapeutic Area : Sleep

                            Study Phase : Phase I

                            Sponsor : Jazz Pharmaceuticals

                            Deal Size : $1,140.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Jazz Pharmaceuticals and Sumitomo Pharma Announce Exclusive License Agreement to Develop and Commercialize DSP...

                            Details : Under the agreement, Jazz will receive an exclusive license to develop and commercialize narcolepsy and sleep drug DSP-0187/JZP441 in U.S., Europe and other territories except Japan, China and other Asia/Pacific countries and regions, where Sumitomo Phar...

                            Brand Name : JZP441

                            Molecule Type : Small molecule

                            Upfront Cash : $50.0 million

                            May 04, 2022

                            Lead Product(s) : DSP-0187

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase I

                            Sponsor : Jazz Pharmaceuticals

                            Deal Size : $1,140.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth